Pharmacogenomics of ovulation induction: Facilitating decisions on who, when and how to treat

Pharmacogenomics

Volumn 10, Issue 9, 2009, Pages 1377-1379

  Overbeek, Annelies ^a   Lambalk, C B ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE CITRATE; FOLLITROPIN; FOLLITROPIN RECEPTOR; METFORMIN; RECOMBINANT FOLLITROPIN; SERINE; TAMOXIFEN;

BIOCHEMISTRY; CLINICAL DECISION MAKING; CLINICAL FEATURE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TREATMENT FAILURE; ECHOGRAPHY; EDITORIAL; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPERANDROGENISM; LOW DRUG DOSE; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PHARMACOGENOMICS; PHENOTYPE; PREDICTION; PREGNANCY; PROTEIN VARIANT;

ADULT; CLOMIPHENE; DECISION MAKING; DRUG RESISTANCE; FEMALE; FERTILITY AGENTS, FEMALE; HUMANS; INFERTILITY, FEMALE; OVULATION INDUCTION; PHARMACOGENETICS; POLYCYSTIC OVARY SYNDROME; PREGNANCY;

EID: 70649105578     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.110     Document Type: Editorial

References (25)

1. Franks S: Diagnosis of polycystic ovarian syndrome: In defense of the Rotterdam criteria. J. Clin. Endocrinol. Metab. 91(3), 786-789 (2006).
2. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 81(1), 19-25 (2004).
3. Azziz R, Carmina E, Dewailly D et al.: The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91(2), 456-488 (2009).
4. Homburg R: The management of infertility associated with polycystic ovary syndrome. Reprod. Biol. Endocrinol. 1, 109 (2003).
5. Fauser BCJM, Diedrich K, Devroey P, on behalf of the Evian Annual Reproduction (EVAR) Workshop Group: Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum. Reprod. Update 14(1), 1-14 (2008).
6. Ghobadi C, Nguyen TH, Lennard MS, Amer S, Rostami-Hodjegan A, Ledger WL: Evaluation of an existing nomogram for predicting the response to clomiphene citrate. Fertil. Steril. 87(3), 597-602 (2007).
7. Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC: Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J. Clin. Endocrinol. Metab. 83(7), 2361-2365 (1998).
8. Imani B, Eijkemans MJ, de Jong FH et al.: Free androgen index and leptin are the most prominent endocrine predictors of ovarian response during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J. Clin. Endocrinol. Metab. 85(2), 676-682 (2000).
9. Kurabayashi T, Suzuki M, Fujita K, Murakawa H, Hasegawa I, Tanaka K: Prognostic factors for ovulatory response with clomiphene citrate in polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 126(2), 201-205 (2006).
10. Palomba S, Falbo A, Orio J, Tolino A, Zullo F: Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome. Fertil. Steril. 91(6), 2557-2567 (2009).
11. Perez MM, Gromoll J, Behre HM, Gassner C, Nieschlag E, Simoni M: Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J. Clin. Endocrinol. Metab. 85(9), 3365-3369 (2000).
12. Behre HM, Greb RR, Mempel A et al.: Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenet. Genomics 15(7), 451-456 (2005).
13. Daelemans C, Smits G, de Maertelaer V et al.: Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. J. Clin. Endocrinol. Metab. 89(12), 6310-6315 (2004).
14. de Castro F, Ruiz R, Montoro L et al.: Role of follicle-stimulating hormone receptor Ser680Asn polymorphism in the efficacy of follicle-stimulating hormone. Fertil. Steril. 80(3), 571-576 (2003).
15. de Castro F, Moron FJ, Montoro L, Real LM, Ruiz A: Pharmacogenetics of controlled ovarian hyperstimulation. Pharmacogenomics 6(6), 629-637 (2005).
16. Douchi T, Oki T, Yamasaki H, Nakae M, Imabayashi A, Nagata Y: Body fat patterning in polycystic ovary syndrome women as a predictor of the response to clomiphene. Acta Obstet. Gynecol. Scand. 83(9), 838-841 (2004).
17. Jun JK, Yoon JS, Ku SY et al.: Follicle-stimulating hormone receptor gene polymorphism and ovarian responses to controlled ovarian hyperstimulation for IVF-ET. J. Hum. Genet. 51(8), 665-670 (2006).
18. Klinkert ER, te Velde ER, Weima S et al.: FSH receptor genotype is associated with pregnancy but not with ovarian response in IVF. Reprod. Biomed. Online 13(5), 687-695 (2006).
19. Loutradis D, Patsoula E, Minas V et al.: FSH receptor gene polymorphisms have a role for different ovarian response to stimulation in patients entering IVF/ ICSI-ET programs. J. Assist. Reprod. Genet. 23(4), 177-184 (2006).
20. Overbeek A, Kuijper EA, Hendriks ML et al.: Clomiphene citrate resistance in relation to follicle-stimulating hormone receptor Ser680Ser-polymorphism in polycystic ovary syndrome. Hum. Reprod. 24(8), 2007-2013 (2009).
21. Valkenburg O, van Santbrink EJP, Themmen APN, Uitterlinden AG, Fauser BC, Laven JSE: FSH receptor polymorphism affects the outcome of ovulation induction in normogonadotropic anovulatory infertility (WHOII). Hum. Reprod. 24(Suppl. 1), I85 (2009).
22. Brauch H, Murdter TE, Eichelbaum M, Schwab M: Pharmacogenomics of tamoxifen therapy. Clin. Chem. (2009) (Epub ahead of print).
23. Overbeek A, Lambalk CB: Phenotypic and pharmacogenetic aspects of ovulation induction in WHO II anovulatory women. Gynecol. Endocrinol. 25(4), 222-234 (2009).
24. Shu Y, Brown C, Castro RA et al.: Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther. 83(2), 273-280 (2008).
25. Legro RS, Barnhart HX, Schlaff WD et al.: Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J. Clin. Endocrinol. Metab. 93(3), 792-800 (2008).